StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

SANOFI — SANOFI INDIA LIMITED

Price History

Data as of 26 Jun 2026· via fincrux

How SANOFI has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Lower end of its 12-month range8% of range

Trading about 46% below its 12-month high — historically cheaper territory for this stock. It sits below its 200-day average, the longer-term trend.

₹3,097 low₹6,187 high
vs 50-day avg
+1.8%
vs 200-day avg
−15.0%
Beginner mode
Plain English, with everything explained

SANOFI

NSE

SANOFI INDIA LIMITED

Healthcare / Pharma

₹3,355.60
0.00%
last close
0%
Quality Score
Looks high-qualityBig money steady

SANOFI INDIA LIMITED clears 2 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹7133.00 Cr
Price tag
21.7×
Money it earns
43.0%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.02goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 43.0%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Watch

Big investors are roughly holding their position, neither rushing in nor out.

FII+DII 26.8%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous Sy…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What SANOFI owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemDec '21Dec '22Dec '23Dec '24Dec '25
Borrowings2524191918
Equity Capital2323232323
Reserves2,2031,253992838726
Total Assets3,0612,0721,7151,6121,255
Total Liabilities3,0612,0721,7151,6121,255

Borrowings trending down

Total borrowings are down about 28% over the last 5 years — the company has been reducing its reliance on debt.

Periodic Performance

Yearly net profit for SANOFI — does it earn money consistently?

Consistently profitable

Every one of the last 5 years has been profitable — a sign of durable earnings.

₹621 Cr
₹603 Cr
₹414 Cr
₹327 Cr
₹310 Cr
Dec '22Dec '23Dec '24Dec '25TTM
rev ₹2,770 Crrev ₹2,851 Crrev ₹2,013 Crrev ₹1,837 Crrev ₹1,774 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about SANOFI — observations, not recommendations.

Strengths

4
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Profitable in every one of the last 5 years.
  • Sits in the lower part of its 12-month range — historically cheaper territory for this stock.

Risks

0

No notable risks flagged by the numbers right now.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
5.7%0.0 pp
DII· Domestic institutions
21.1%-1.9 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector